Published in Cancer Res on January 15, 2009
Mammalian polyamine metabolism and function. IUBMB Life (2009) 2.33
Non-canonical Hedgehog/AMPK-Mediated Control of Polyamine Metabolism Supports Neuronal and Medulloblastoma Cell Growth. Dev Cell (2015) 1.49
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med (2010) 1.35
Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis. PLoS Genet (2012) 1.31
Preclinical models for neuroblastoma: establishing a baseline for treatment. PLoS One (2011) 1.09
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07
Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer. Mol Cancer Res (2011) 1.00
Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. Semin Cancer Biol (2011) 0.96
Unbiased metabolite profiling indicates that a diminished thymidine pool is the underlying mechanism of colon cancer chemoprevention by alpha-difluoromethylornithine. Cancer Discov (2013) 0.95
The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer (2010) 0.95
Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma. Clin Cancer Res (2009) 0.92
Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling. Cancer Prev Res (Phila) (2014) 0.91
Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma. Front Oncol (2012) 0.89
c-MYC-induced genomic instability. Cold Spring Harb Perspect Med (2014) 0.89
Therapeutic targets for neuroblastomas. Expert Opin Ther Targets (2014) 0.87
DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. Int J Oncol (2013) 0.85
Novel interaction of ornithine decarboxylase with sepiapterin reductase regulates neuroblastoma cell proliferation. J Mol Biol (2013) 0.80
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma. PLoS One (2015) 0.79
Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.79
Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma. Transl Pediatr (2015) 0.79
S-adenosylmethionine decarboxylase overexpression inhibits mouse skin tumor promotion. Carcinogenesis (2012) 0.76
Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target. BMC Cancer (2015) 0.76
Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma? Eur J Clin Pharmacol (2011) 0.75
Polyamines directly promote antizyme-mediated degradation of ornithine decarboxylase by the proteasome. Microb Cell (2015) 0.75
Cell Proliferation in Neuroblastoma. Cancers (Basel) (2016) 0.75
Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol (2014) 0.75
Identifying novel therapeutic agents using xenograft models of pediatric cancer. Cancer Chemother Pharmacol (2016) 0.75
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 17.38
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (1986) 14.56
A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res (1991) 13.54
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 9.79
Genomic targets of the human c-Myc protein. Genes Dev (2003) 9.67
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (1984) 9.64
Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell (1999) 8.03
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med (1985) 7.79
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) (2008) 5.82
Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature (2002) 5.25
Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J (1997) 4.99
Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer (2004) 4.70
Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. Genes Dev (2003) 4.68
The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci U S A (1993) 4.66
c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature (2001) 4.46
Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity (2001) 4.09
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med (2001) 3.51
Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell (2002) 2.99
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res (2006) 2.42
Regulation of ornithine decarboxylase. J Biol Chem (2006) 2.27
Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell (2005) 1.95
Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling. Nature (1991) 1.83
The ornithine decarboxylase gene is essential for cell survival during early murine development. Mol Cell Biol (2001) 1.65
c-Myc induces the expression and activity of ornithine decarboxylase. Cell Growth Differ (1993) 1.60
Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. Proc Natl Acad Sci U S A (1993) 1.55
Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res (1997) 1.49
Neurofibromatosis type 1 gene mutations in neuroblastoma. Nat Genet (1993) 1.48
Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol Cell (2003) 1.47
Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol (2003) 1.47
Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res (2006) 1.40
Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO J (2007) 1.29
Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J (2002) 1.26
Polyamine depletion arrests cell cycle and induces inhibitors p21(Waf1/Cip1), p27(Kip1), and p53 in IEC-6 cells. Am J Physiol (1999) 1.24
Myc target transcriptomes. Curr Top Microbiol Immunol (2006) 1.23
Biological classification of cell lines derived from human extra-cranial neural tumors. Prog Clin Biol Res (1988) 1.18
Polyamine depletion in human melanoma cells leads to G1 arrest associated with induction of p21WAF1/CIP1/SDI1, changes in the expression of p21-regulated genes, and a senescence-like phenotype. Cancer Res (2001) 1.16
The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev (2008) 1.15
Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res (2007) 1.11
Human myeloma cells acquire resistance to difluoromethylornithine by amplification of ornithine decarboxylase gene. Biochem J (1987) 1.01
Co-operation between follicular ornithine decarboxylase and v-Ha-ras induces spontaneous papillomas and malignant conversion in transgenic skin. Carcinogenesis (1998) 1.00
K6/ODC transgenic mice as a sensitive model for carcinogen identification. Toxicol Lett (2000) 0.98
Haploinsufficiency for odc modifies mouse skin tumor susceptibility. Cancer Res (2005) 0.94
Effects of overexpression of ornithine decarboxylase (ODC) on growth control and oncogene-induced cell transformation. Oncogene (1991) 0.90
Inhibition of murine embryonic development by alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase. Eur J Pharmacol (1980) 0.86
Effects of gestational or neonatal treatment with alpha-difluoromethylornithine on ornithine decarboxylase and polyamines in developing rat brain and on adult rat neurochemistry. Exp Brain Res (1996) 0.81
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell (2003) 7.60
Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature (2007) 7.21
NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc Natl Acad Sci U S A (2007) 5.14
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood (2007) 4.91
A compendium of RNA-binding motifs for decoding gene regulation. Nature (2013) 4.91
Measuring patients' trust in physicians when assessing quality of care. Health Aff (Millwood) (2004) 3.92
Toward a 21st-century health care system: recommendations for health care reform. Ann Intern Med (2009) 3.85
Myc pathways provoking cell suicide and cancer. Oncogene (2003) 3.49
c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev (2002) 3.16
Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest (2008) 2.83
Regulation of cell cycle progression and gene expression by H2A deubiquitination. Nature (2007) 2.52
Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis. J Clin Invest (2002) 2.50
Mitochondrial clearance is regulated by Atg7-dependent and -independent mechanisms during reticulocyte maturation. Blood (2009) 2.39
Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood (2004) 2.30
Development of abbreviated measures to assess patient trust in a physician, a health insurer, and the medical profession. BMC Health Serv Res (2005) 2.18
Targeting lactate metabolism for cancer therapeutics. J Clin Invest (2013) 2.14
Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci U S A (2003) 2.07
Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell (2005) 1.95
Mitochondrial dysfunction in ataxia-telangiectasia. Blood (2011) 1.93
Development of a scale to measure patients' trust in health insurers. Health Serv Res (2002) 1.91
Hsp90-Cdc37 chaperone complex regulates Ulk1- and Atg13-mediated mitophagy. Mol Cell (2011) 1.91
Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J (2003) 1.85
Trust and satisfaction with physicians, insurers, and the medical profession. Med Care (2003) 1.77
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood (2010) 1.76
Qiliqiangxin improves cardiac function in spontaneously hypertensive rats through the inhibition of cardiac chymase. Am J Hypertens (2011) 1.74
Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol (2008) 1.72
Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. EMBO J (2005) 1.68
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol (2013) 1.66
Gene selection from microarray data for cancer classification--a machine learning approach. Comput Biol Chem (2005) 1.64
Views of potential research participants on financial conflicts of interest: barriers and opportunities for effective disclosure. J Gen Intern Med (2006) 1.63
Pseudoporphyria as a result of voriconazole use: a case report. Int J Dermatol (2004) 1.61
An integrated in silico gene mapping strategy in inbred mice. Genetics (2006) 1.60
c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol Cell Biol (2003) 1.59
Attitudes of African American and low socioeconomic status white women toward medical research. J Health Care Poor Underserved (2007) 1.58
In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. Blood (2004) 1.58
How patients' trust relates to their involvement in medical care. J Fam Pract (2005) 1.53
Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation. PLoS One (2011) 1.53
Retracted FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol (2005) 1.51
The study of ISO induced heart failure rat model. Exp Mol Pathol (2009) 1.50
Patient reactions to confidentiality, liability, and financial aspects of informed consent in cardiology research. Circ Cardiovasc Qual Outcomes (2010) 1.50
Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol Cell (2003) 1.47
Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis. Cancer Res (2013) 1.46
Policies of academic medical centers for disclosing financial conflicts of interest to potential research participants. Acad Med (2006) 1.43
The impact of Blue Cross conversions on health spending and the uninsured. Health Aff (Millwood) (2005) 1.41
Long-term outcomes of stent placement for symptomatic nonthrombotic iliac vein compression lesions in chronic venous disease. J Vasc Interv Radiol (2012) 1.39
Percutaneous endovenous treatment of congenital extratruncular venous malformations with an ultrasound-guided and 810-nm diode laser. J Vasc Surg (2011) 1.39
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood (2008) 1.31
Modulating autophagy for therapeutic benefit. Autophagy (2007) 1.30
Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO J (2007) 1.29
Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state. Cell (2012) 1.29
Regulation of histone H2A and H2B deubiquitination and Xenopus development by USP12 and USP46. J Biol Chem (2010) 1.28
Effects of disclosing financial interests on attitudes toward clinical research. J Gen Intern Med (2008) 1.23
Mapping the phosphorylation sites of Ulk1. J Proteome Res (2009) 1.21
Spatial mapping of thymic stromal microenvironments reveals unique features influencing T lymphoid differentiation. Immunity (2009) 1.20
SCL is required for normal function of short-term repopulating hematopoietic stem cells. Blood (2004) 1.20
Disclosing conflicts of interest in clinical research: views of institutional review boards, conflict of interest committees, and investigators. J Law Med Ethics (2006) 1.19
Persistent degenerative changes in thymic organ function revealed by an inducible model of organ regrowth. Aging Cell (2011) 1.17
Activation of the ATM-Snail pathway promotes breast cancer metastasis. J Mol Cell Biol (2012) 1.16
Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis. Mol Cancer Res (2007) 1.16
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate (2011) 1.13
Clearing the TRAIL for Cancer Therapy. Cancer Cell (2007) 1.13
Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation. Mol Cell Biol (2004) 1.13
The impact of local immigration enforcement policies on the health of immigrant hispanics/latinos in the United States. Am J Public Health (2015) 1.11
Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res (2007) 1.09
IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol (2009) 1.08
An exploration of patients' trust in physicians in training. J Health Care Poor Underserved (2004) 1.07
Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma. Cancer (2011) 1.07
Disclosure of financial relationships to participants in clinical research. N Engl J Med (2009) 1.06
Robust signals of coevolution of interacting residues in mammalian proteomes identified by phylogeny-aided structural analysis. Nat Genet (2005) 1.05
Loss of Bax alters tumor spectrum and tumor numbers in ARF-deficient mice. Cancer Res (2002) 1.05
A Myc-Slug (Snail2)/Twist regulatory circuit directs vascular development. Development (2008) 1.05
The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis. Mol Cell Biol (2005) 1.04
Developing model language for disclosing financial interests to potential clinical research participants. IRB (2007) 1.03
Comparison of conflict of interest policies and reported practices in academic medical centers in the United States. Account Res (2007) 1.03
Forests and drugs: coca-driven deforestation in tropical biodiversity hotspots. Environ Sci Technol (2011) 1.03
Chlamydia species-dependent differences in the growth requirement for lysosomes. PLoS One (2011) 1.01
Aberrant mast-cell differentiation in mice lacking the stem-cell leukemia gene. Blood (2007) 1.01
Essential role of phospholipase C gamma 2 in early B-cell development and Myc-mediated lymphomagenesis. Mol Cell Biol (2006) 1.01
Redundant ubiquitin ligase activities regulate wee1 degradation and mitotic entry. Cell Cycle (2007) 1.00
MicroRNA-221 and -222 regulate radiation sensitivity by targeting the PTEN pathway. Int J Radiat Oncol Biol Phys (2011) 1.00